130 related articles for article (PubMed ID: 16311736)
1. Complete remission and successful stem cell mobilization after treatment of refractory plasma cell leukemia with bortezomib.
Grassinger J; Südhoff T; Andreesen R; Hennemann B
Ann Hematol; 2006 Feb; 85(2):132-3. PubMed ID: 16311736
[No Abstract] [Full Text] [Related]
2. Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?
Katodritou E; Verrou E; Gastari V; Hadjiaggelidou C; Terpos E; Zervas K
Leuk Res; 2008 Jul; 32(7):1153-6. PubMed ID: 18083228
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of bortezomib in patients with plasma cell leukemia.
Musto P; Rossini F; Gay F; Pitini V; Guglielmelli T; D'Arena G; Ferrara F; Filardi N; Guariglia R; Palumbo A; ; ;
Cancer; 2007 Jun; 109(11):2285-90. PubMed ID: 17469169
[TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia.
Kim SJ; Kim J; Cho Y; Seo BK; Kim BS
Jpn J Clin Oncol; 2007 May; 37(5):382-4. PubMed ID: 17538191
[TBL] [Abstract][Full Text] [Related]
5. Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia.
Jaskiewicz AD; Herrington JD; Wong L
Pharmacotherapy; 2005 Dec; 25(12):1820-5. PubMed ID: 16305302
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib is effective in primary plasma cell leukemia.
Finnegan DP; Kettle P; Drake M; Matthews C; Alexander HD; Popat R; Cavanagh JD; Wachsman W; Morris TC
Leuk Lymphoma; 2006 Aug; 47(8):1670-3. PubMed ID: 16966282
[No Abstract] [Full Text] [Related]
7. Durable complete remission of primary plasma cell leukemia with the bortezomib plus melphalan and prednisone (VMP) regimen.
Libby E; Candelaria-Quintana D; Moualla H; Abdul-Jaleel M; Rabinowitz I
Am J Hematol; 2010 Sep; 85(9):733-4. PubMed ID: 20669178
[No Abstract] [Full Text] [Related]
8. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
Faderl S; Rai K; Gribben J; Byrd JC; Flinn IW; O'Brien S; Sheng S; Esseltine DL; Keating MJ
Cancer; 2006 Sep; 107(5):916-24. PubMed ID: 16832816
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation.
Bruno B; Patriarca F; Sorasio R; Mattei D; Montefusco V; Peccatori J; Bonifazi F; Petrucci MT; Milone G; Guidi S; Giaccone L; Rotta M; Fanin R; Boccadoro M; Corradini P;
Haematologica; 2006 Jun; 91(6):837-9. PubMed ID: 16769588
[TBL] [Abstract][Full Text] [Related]
10. VAD combination chemotherapy followed by bortezomib may be an effective treatment in secondary plasma cell leukemia.
Ataergin S; Arpaci F; Kaya A; Cetin T; Gunhan O
Am J Hematol; 2006 Dec; 81(12):987-8. PubMed ID: 16888783
[No Abstract] [Full Text] [Related]
11. Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy.
Al-Nawakil C; Tamburini J; Bardet V; Chapuis N; Bourry E; Roux C; Park S; Choquet S; Dreyfus F; Bouscary D
Leuk Lymphoma; 2008 Oct; 49(10):2012-4. PubMed ID: 18720213
[No Abstract] [Full Text] [Related]
12. [Clinical analysis of bortezomib combined with chemotherapy for one case of refractory acute lymphocytic leukemia].
Xu JJ; Hu XH; Shen YY
Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):697-8. PubMed ID: 22339831
[No Abstract] [Full Text] [Related]
13. Complete remission with bortezomib on plasmocytomas in an end-stage patient with refractory multiple myeloma who failed all other therapies including hematopoietic stem cell transplantation: possible enhancement of graft-vs-tumor effect.
Paubelle E; Coppo P; Garderet L; Azizi L; Bories D; Gorin NC; Fouillard L
Leukemia; 2005 Sep; 19(9):1702-4. PubMed ID: 16001088
[No Abstract] [Full Text] [Related]
14. Medullary renal cell carcinoma and response to therapy with bortezomib.
Ronnen EA; Kondagunta GV; Motzer RJ
J Clin Oncol; 2006 Mar; 24(9):e14. PubMed ID: 16549825
[No Abstract] [Full Text] [Related]
15. Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series.
Wolf J; Richardson PG; Schuster M; LeBlanc A; Walters IB; Battleman DS
Clin Adv Hematol Oncol; 2008 Oct; 6(10):755-60. PubMed ID: 18997666
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of bortezomib in combination chemotherapy on secondary plasma cell leukemia.
Ali R; Beksac M; Ozkalemkas F; Ozkocaman V; Ozkan A; Ozcelik T; Tunali A
Leuk Lymphoma; 2007 Jul; 48(7):1426-8. PubMed ID: 17613776
[No Abstract] [Full Text] [Related]
17. Side effects and good effects from new chemotherapeutic agents. Case 3. Bortezomib in primary refractory plasmacytoma.
Chim CS; Ooi GC; Loong F; Au AW; Lie AK
J Clin Oncol; 2005 Apr; 23(10):2426-8. PubMed ID: 15800336
[No Abstract] [Full Text] [Related]
18. Effectiveness and safety of high-dose cyclophosphamide as salvage therapy for high-risk multiple myeloma and plasma cell leukemia refractory to new biological agents.
Rivell GL; Brunson CY; Milligan L; Stuart RK; Costa LJ
Am J Hematol; 2011 Aug; 86(8):699-701. PubMed ID: 21630309
[No Abstract] [Full Text] [Related]
19. Bortezomib in multiple myeloma.
Mateos MV; San Miguel JF
Best Pract Res Clin Haematol; 2007 Dec; 20(4):701-15. PubMed ID: 18070714
[TBL] [Abstract][Full Text] [Related]
20. [Bortezomib].
Simons S; Scheulen ME; Jaehde U
Dtsch Med Wochenschr; 2006 Feb; 131(5):214-8. PubMed ID: 16440269
[No Abstract] [Full Text] [Related]
[Next] [New Search]
